New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
09:16 EDTJNJ, LOGI, FTNT, UA, QCOM, ANGI, GM, TRIP, SKX, DNKN, ONVO, SRPT, VDSI, CAT, F, FBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Facebook (FB), up 7.6%... Ford (F), up 1.4%... Skechers (SKX), up 8%... Under Armour (UA), up 8.5%... VASCO (VDSI), up 16.6%... Logitech (LOGI), up 14.4%... Fortinet (FTNT), up 9%. ALSO HIGHER: Organovo (ONVO), up 19.6% after entering a 3D bio-printed tissue agreement with a unit of J&J (JNJ). DOWN AFTER EARNINGS: General Motors (GM), down 2.4%... Dunkin' Brands (DNKN), down 7.8%... TripAdvisor (TRIP), down 9.7%... Qualcomm (QCOM), down 5.5%... Caterpillar (CAT), down 2.8%. ALSO LOWER: Angie's List (ANGI), down 18% after Q2 report last night, at least seven downgrades of stock this morning... Sarepta (SRPT), down 6.3% after terminating Chief Scientific Officer Arthur Krieg.
News For FB;GM;F;ONVO;ANGI;CAT;DNKN;QCOM;VDSI;SKX;UA;SRPT;TRIP;JNJ;FTNT;LOGI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>
August 20, 2015
19:35 EDTFBGoogle tests video ads in search results, Digiday says
Subscribe for More Information
16:00 EDTFBOptions Update; August 20, 2015
iPath S&P 500 VIX Short-Term Futures up 1.49 to 17.70. Option volume leaders: AAPL BAC FB NFLX DIS INTC BABA MU
12:56 EDTFBSmall drones bringing air traffic problems in U.S., Washington Post reports
Subscribe for More Information
11:49 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX
11:33 EDTJNJLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
11:16 EDTFBStocks with call strike movement; FB NFLX
Subscribe for More Information
10:32 EDTFBFacebook August calls active
Facebook August 94 & 95 calls are active on total call volume of 84K contracts (36K puts). August call option implied volatility is at 41, August weekly is at 33, September is at 30; compared to its 52-week range of 20 to 48. Active call volume suggests traders taking positions for upside price movement.
10:14 EDTFFord reports Europe sales up 5.3% in July
Subscribe for More Information
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
06:45 EDTSKXSkechers volatility increases as shares near record high
Skechers August call option implied volatility is at 40, September is at 36; compared to its 52-week range of 27 to 58, suggesting non-directional price movement.
August 19, 2015
16:00 EDTFBOptions Update; August 19, 2015
Subscribe for More Information
13:35 EDTGMGM investing C$12M for added Chevrolet Equinox production at Oshawa Assembly
GM Canada president and managing director Steve Carlisle announced that GM will invest C$12M to increase Chevrolet Equinox production on the Consolidated production line at Oshawa Assembly and for related changes in the body shop at CAMI Assembly. This further investment in Ontario-based production and supplier tools will help to meet strong North American customer demand for the Chevrolet Equinox. The investment extends plans for ongoing Oshawa Assembly Consolidated Line production to 2017. GM has invested approximately C$800M in its Oshawa and St. Catharines operations over the past 3 years and recently announced a further $800M investment in its CAMI operation in Ingersoll, Ontario.
10:00 EDTLOGIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Biocept (BIOC) initiated with a Buy at H.C. Wainwright... C.H. Robinson (CHRW) initiated with a Buy at Evercore ISI... Chipotle (CMG) initiated with a Hold at Maxim... Con-way (CNW) initiated with a Buy at Evercore ISI... Dermira (DERM) initiated with an Outperform at Cowen... Expeditors (EXPD) initiated with a Hold at Evercore ISI... Fleetmatics (FLTX) initiated with an In-Line at Imperial Capital... Frontier Communications (FTR) initiated with an Overweight at Stephens... Gevo (GEVO) initiated with a Buy at Rodman & Renshaw... International Game (IGT) initiated with a Sell at Goldman... Knight Transportation (KNX) initiated with a Buy at Evercore ISI... Logitech (LOGI) initiated with a Buy at Rosenblatt... Navistar (NAV) initiated with a Neutral at Macquarie... Panera Bread (PNRA) initiated with a Hold at Maxim... Scientific Games (SGMS) initiated with a Sell at Goldman... Swift Transport (SWFT) initiated with a Hold at Evercore ISI... Tribune Media (TRCO) initiated with an Equal Weight at Morgan Stanley... WEX Inc. (WEX) initiated with an Equal Weight at Barclays... Zoe's Kitchen (ZOES) initiated with a Buy at Maxim.
09:33 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL BAC FB BA TWTR NFLX WMT BABA
09:17 EDTSRPT'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:55 EDTLOGILogitech initiated with a Buy at Rosenblatt
Target $18.
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
06:53 EDTFBDeutsche Telekom exec calls for internet firms to subsidize online ads, FT says
Deutsche Telekom (DTEGY) senior vice president of technology strategy, governance, and programs Tomasz Gerszberg has called for internet companies such as Google (GOOG) and Facebook (FB) to subsidize users' mobile subscriptions due to the new way advertising takes over data allowances, the Financial Times reports, citing an article Gerszberg wrote on LinkedIn. The Deutsche Telekom executive said that consumers need to be protected from rising data charges related to "annoying" online ads, the report says. Reference Link
06:18 EDTQCOMQualcomm exec among casualties in midair plane crash, AP reports
Subscribe for More Information
06:12 EDTDNKNStarbucks K-cup momentum is accelerating, says UBS
UBS analyst Keith Siegner says Starbucks (SBUX) is seeing accelerating momentum in the single-serve cup category. The company's K-cup sales increased 36% year-over-year for the four-week period ended August 8, according to Nielsen (NLSN), Siegner tells investors in a research note. Starbucks' K-cup promotion levels ticked up sequentially, but remain well below levels from earlier in the year, the analyst points out. The company's K-Cup portfolio continues to gain share despite increasing price pressure and new market entrants like Dunkin' Brands (DNKN) and McDonald's (MCD), Siegner writes. He keeps a Buy rating on Starbucks with a $63 price target. The stock closed yesterday up 9c to $57.83. Shares of Keurig Green Mountain (GMCR) are down 62% year-to-date in part due to the company's slowing sales in the single-serve cup category.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use